Merial has launched a brand new equine pain management product. Equioxx is the first COX-2 specific NSAID for horses and follows on from Previcox, the canine NSAID.

Merial has launched a brand new equine pain management product. Equioxx is the first COX-2 specific NSAID for horses and follows on from Previcox, the canine NSAID.

HOW IS EQUIOXX DIFFERENT ?
Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Equioxx is the only NSAID that is highly COX-2 selective, acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels. In fact Equioxx is up to 643 times more selective for COX-2 than COX-1.

EquioxxPROVEN EFFICACY
Equioxx contains the active ingredient firocoxib, and is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows convenient once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.

Equioxx is highly COX-2 selective and is available as either a low dose injectable solution or a palatable oral paste.

For more information contact Merial customer services on 0870 6000 123

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz